Second time also unlucky for Astellas and Vical's herpes vaccine

22 January 2018

California’s Vical (Nasdaq: VICL) says its Phase III HELIOS trial of DNA vaccine ASP0113 has flopped. Shares are down almost a quarter ahead of the opening bell in New York.

The vaccine, which has been designated an orphan drug in the USA and in the European Union, is being developed as a vaccine against the herpes-causing cytomegalovirus, as part of an up to-$130 million 2011 collaboration with Astellas (TYO: 4503).

Bernhardt Zeiher, president of development at Astellas, said he was “disappointed that the results did not demonstrate a significant improvement in overall survival and reduction in CMV end-organ disease.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK